Novabay Pharmaceuticals Inc.
13F holders, Q2 2025 (June 30)13holders −5
1new positions
6sold out
$0.58avg. 13F price*
At the end of Q2 2025, 13 institutions reported holding Novabay Pharmaceuticals Inc. in their 13F filings, down 5 from Q1 2025. 1 opened new positions and 6 sold out. The largest holders were C2C Wealth Management, LLC ($57K), Geode Capital Management, LLC ($20K) and Rangeley Capital, LLC ($19K).
- Company
- Novabay Pharmaceuticals Inc.
- CUSIP
- 66987P409
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $19K |
| Exits | 6 | $134K |
All 13F filers, Q1 2025 → Q2 2025: 86,128 shares bought and 229,846 shares sold, net −143,718 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| C2C Wealth Management, LLC | 0.05% | Add +78.2% | 98,000 | $57K |
| Geode Capital Management, LLC | 0.00% | Reduce -3.4% | 33,823 | $20K |
| Rangeley Capital, LLC | 0.03% | New | 33,210 | $19K |
| Two Sigma Securities, LLC | 0.00% | Add +39.0% | 24,280 | $14K |
| XTX Topco Ltd | 0.00% | Add +2.3% | 20,310 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -0.1% | 5,451 | $3K |
| UBS Group AG | 0.00% | Add +351.9% | 3,385 | $2K |
| Bank of America Corp. | 0.00% | Add +27.9% | 55 | $31 |
| Morgan Stanley | 0.00% | Reduce -50.0% | 3 | $2 |
| Nvwm, LLC | 0.00% | No change | 3 | $2 |
| Northwestern Mutual Wealth Management Co. | 0.00% | No change | 1 | $1 |
| Addison Advisors LLC | 0.00% | No change | 1 | $1 |
| Royal Bank of Canada | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is NOVABAY PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Novabay Pharmaceuticals Inc. the manager owns.